



INTELLECTUAL
PROPERTY OFFICE
BRUNEI DARUSSALAM

28 February 2022

NO. 002/2022



PATENT JOURNAL

Brunei Darussalam Intellectual Property Office (BrulPO)

The Law Building, Ground Floor

Jalan Raja Isteri Pengiran Anak Saleha

Bandar Seri Begawan BA1910

Negara Brunei Darussalam

Tel: +673 2244873/4/5/6 Ext 102

Email: enquiries@bruipo.gov.bn

Brunei Darussalam Intellectual Property Office (BrulPO) © 2013. All rights reserved. Modification or reproduction of this Journal without the permission of BrulPO is prohibited.





CONTENTS

General Information	3
Operating Hours	3
Submission of Application	3
Enquiries	3
Patents Legislation	4
Forms and Fees	4
INID Codes	5
First Schedule – Fees	7
Second Schedule – Forms	15
Third Schedule – Scale of Cost Part 1 – Basic Costs	19
Part II – Additional Cost	20
Fourth Schedule – Micro-Organisms	21
Fifth Schedule – Remuneration of Scientific Advisers	27
New Patent Applications Filed	34
Patent Renewal Application	62
Patent Granted	74
Patent Recordal of Change of Name	77



General Information

The Brunei Darussalam Intellectual Property Office (BruIPO) is an Office under the Attorney General's Chamber and its premises with effect from the 1 April, 2019 and is situated at the following address:

Brunei Darussalam Intellectual Property Office (BruIPO)
Attorney General's Chamber
The Law Building,
Jalan Raja Isteri Pengiran Anak Hajah Saleha,
Bandar Seri Begawan BA1910
Brunei Darussalam
Tel: +673 2225919

Opening Hours

With effect from 1 January, 2020, the Brunei Intellectual Property Office (BruIPO) counter will operate as follows:

Monday to Thursday	: 8.00am to 12.00pm 2.00pm to 3.00pm
Saturday	: 8.00am to 11.00am
Friday and Sunday	: CLOSED

Submission of Applications

1. All applications for the registration of patents must be lodged with the Registrar of Patents at the Brunei Darussalam Intellectual Property Office (BruIPO).
2. Submission of applications via fax is acceptable provided the documents transmitted are clear and legible (in particular, representations). For applications that require the payment of a fee, actual lodgement of the prescribed fee is required before such applications can be processed.

Enquiries

1. For enquiries relating to any information in this Journal, kindly contact the Office at telephone numbers +673 2225919. Hard copies of the Journal can be purchased upon request from the Office at a cost of B\$10.00 per copy.
2. The website of the Brunei Darussalam Intellectual Property Office (BruIPO) is <http://www.bruipo.gov.bn>.
3. All Patent-related enquiries via email can be submitted to enquiries@bruipo.gov.bn



Patents Legislation

1. The legislation governing the registration of Patent in Brunei Darussalam is the Patents Order 2011, while the subsidiary legislation is the Patents Rule, 2012.
2. The hard copies of the legislation can be purchased from: Print Plus Sdn Bhd Prime Minister's Office Jalan Airport Lama Bandar Seri Begawan BB3510 Brunei Darussalam Tel: 238 2541
3. The soft copies of the legislation can be obtained from www.bruipo.gov.bn

Forms and Fees

1. For any proceedings before the Registry, the prescribed form to be used and the accompanying fee payable shall be in accordance with the First and Second Schedule of the Patents Rule, 2012.
2. Payment by cheque should be made out to 'THE GOVERNMENT OF BRUNEI DARUSSALAM'.

Restrictions on Applications Abroad by Residents of Brunei Darussalam

1. Local applicants intending to file a patent abroad must first obtain the Registrar's written authority as prescribed under section 33(1) of the Patents Order, 2011.
2. Failure to observe this requirement is an offence under section 33(1)(b)(3) of the Order.

Transitional Applications

1. Transitional applications under Section 115 shall be lodged with the Registrar of Patents in the following manner:
 - Request to the Registrar of Patents for re-registration of a Singapore, Malaysia or United Kingdom/European patent;
 - Lodgement of Patent Form PF46;
 - Certified true copy of the grant of patent in the relevant country;
 - Prescribed fee of B\$250.00; and
 - Any other supporting documents that the Registrar deems necessary.
2. The filing of a Power of Attorney accompanying a request for re-registration is no longer a requirement with effect from 1 January 2012.



3. Any renewal due for patents registered under the repealed Inventions Act (Cap 72) on or after 1 January 2012 shall be made in accordance with Section 54 on Patents Form PF20. Applicants must furnish supporting documents proving the validity of the patents which are due for renewal.

4. Search on the Register of patents (re-registrations) can be conducted at the Office by completing a Search Form PF30 and the payment of a search fee of \$6.50 per hour.



'INID' NUMBERS IN USE ON BRUNEI PATENT DOCUMENTS

'INID' is an acronym for Internationally agreed Numbers for the Identification of Data'

(10) Document identification

- (11) Number of the document
- (12) Plain language designation of the kind of document
- (19) WIPO country code, or other identification, of the country publishing the document.

(20) Document filing data

- (21) Number(s) assigned to the application(s)
- (22) Date(s) of filing application(s)
- (23) Other date(s) of filing, including exhibition filing date and date of filing complete specification following provisional specification.
- (24) Date from which industrial property rights may have effect.

(30) Priority data

- (31) Number(s) assigned to priority application(s).
- (32) Date(s) of filing priority application(s).
- (33) Country (countries) in which the priority application(s) was (were) filed.

(40) Date(s) of making available to the public

- (43) Date of publication by printing or similar process of unexamined document, on which no grant has taken place on or before the said date.
- (44) Date of publication by printing or similar process of an examined document, on which no grant has taken place on or before the said date.
- (45) Date of publication by printing or similar process of a document, on which grant has taken place on or before the said date.
- (47) Date of making a granted patent available to the public by viewing, or copying on request

(50) Technical information

- (51) International Patent Classification
- (52) Domestic or national classification
- (54) Title of invention
- (56) List of prior art documents, if separate from descriptive text.
- (57) Abstract or claim.

(60) Reference(s) to other legally related domestic document(s)

- (60) Related by cognate(s).
- (61) Related by addition(s).
- (62) Related by division(s).

(70) Identification of parties concerned with the document



- (70) Name(s) of nominated person
- (71) Name(s) of applicant(s).
- (72) Name(s) of inventor(s) if known to be such.
- (74) Name(s) of attorney(s) or agent(s).
- (75) Name(s) of inventor(s) who is (are) also applicant(s)

(80) Identification of data related to International Conventions other than the Paris Convention

- (86) PCT Application Number.
- (87) PCT Publication Number.

NOTE

- (1) The classification used is the International Patent Classification and is identified by the INID code (51). Further editions of the classification are identified as (51)2, (51)3, (51)4 and (51)5.
- (2) INID code 74 provides for the name of patent attorney, or firm of attorneys, prosecuting an application.



PRACTICE NOTE 2012/01

PATENT RENEWALS

• RENEWAL OF PATENTS REGISTERED UNDER SECTION 115 OF THE PATENTS ORDER

1. For Section 115 applications, the following original documents need to be signed and submitted to the Registry of Patents:

- (a) PF20;
- (b) PF46 (for the first instance of renewal payment if that agent is not previously appointed);
- (c) evidence of the original patent not having been revoked, and
- (d) a cheque drawn on a Brunei bank account including the correct fee for both the PF20 and PF46. Cheques must be made payable to 'THE GOVERNMENT OF BRUNEI DARUSSALAM'.

2. PF20

The notes at the top of the form and applicable provisions in the Patents Order and Patent Rules should be followed strictly. Additional formatting guidelines are as follows:

Section 2: Brunei registration number in format RP/XX/YYYY for pre 2012 cases, and RE YYYY/XXXX for 2012 onwards.

Section 3: Original Patent number in the format UK: GBXXXXXXX or EPXXXXXXX; MY: MY-XXXXXX-A; and SG: XXXXX.

Section 4: This should match the current details on the Brunei Register (rather than the original patent register details).

Section 5: Agents attending to the renewal on behalf of the proprietor should leave Section 5 blank and instead fill in details in Section 7 and 8.

Section 6: The renewal deadline is calculated from the date of filing for all UK, MY and SG original cases.

3. PF46

Section 6: Most commonly the appointment is for renewal matters only, so the "for renewals only" box should be checked, assuming the agent has not been previously appointed.

4. PF21

Extension fees will become payable for renewals as of 1 January 2013.

5. Certification of original patent

Evidence must be provided that the original patent must not be "revoked" as of the date of the renewal being paid. Please note it does not matter if the original patent has "lapsed" or "ceased". Evidence can be in the form of a certified true copy of the applicable online register printed on the day of filing or a



statutory declaration to the same effect. The online register of the original patent can be printed and certified as a true copy by the authorised agent for the renewal using a suitable chop and signature.

- **EXPIRY OF PATENT AT THE END OF THE TERM OF THE PATENT**

6. Agents are reminded that under Section 115(4)(a), the term of a Section 115 patent is 20 years from the date of filing of the original (UK/MY/SG) patent; subject to Section 35 and 36. It does not make any difference which country the original patent is from.

AMENDMENT OF RULE 92 OF S 19/2012

Rule 92 of the Patent Rules, 2012, is amended by repealing sub-rule (1) and by substituting the following new sub-rule therefor –

“(1) Subject to this rule, in relation to an international application for a patent (Brunei Darussalam) which is, under section 82, to be treated as an application for a patent under the Order, the prescribed period for the purpose of section 83(3) and (5) shall be, in a case where Brunei Darussalam has been designated and/or elected in accordance with the Patent Co-operation Treaty, 30 months from the relevant date.”.

AMENDMENTS AND CORRECTIONS

- **AMENDMENT OF SPECIFICATION (RULES 51) OR CORRECTION OF ERROR IN SPECIFICATION (RULE 64)**


1. Unless required by the Registry under rules 51, an application for amendment of specification or a request for correction of an error in proposed amendment/correction incorporated; only a copy of the specification with the amendment/ correction indicated clearly therein is required. If a copy of the specification with the proposed amendment/correction incorporated is nonetheless filed, please be informed that the Registry will not review that document or consider it in any proceedings before the Registry.
2. The registry would also like to point out the replacement sheets with clear markings will reduce the need for clarification or further correspondences and hence will help expedite the processing of such requests.

- **AMENDMENTS/CORRECTIONS TO SPECIFICATION AND ABSTRACT**


1. Amendments/corrections to patent specifications and abstracts are to be clearly marked and completed by striking through text/figure etc. to be replaced, and by underlining replacement text/figure etc.
2. The following 3 examples reflect 3 possible alternative ways to which the changes could be represented. Example 4 reflects a situation where Patents Form 19 is filed.



Example 1: Page 10 of 19 sheets (Specification) is amended




Example 2: Page 10 of 19 sheets (Specification) is amended






Example 3: Page 10 of 19 sheets (Specification) is amended



This vertical line indicates the matter replacing the whole of page 10. To facilitate the document reproduction process however, the line should be placed about 0.5 cm to 1cm away from the 2.5 cm margin of each sheet.

Example 4: Page 10 of 19 sheets (Specification) is amended





- **COMMONLY MADE MISTAKES WHEN FILING PATENTS FORM 17**

The following are some of the commonly made mistakes in relation to making a request for amendments –

- Replacement sheets for amendments are not filed with Patents Form 17. –
- There is no marked up copy enclosed with Patents Form 17. –
- Patents Form 17 is filed without any replacement sheet. -
- Amendments to be made given on Patents Form 17 are different from the replacement sheets.

REGISTRATION UNDER SECTION 115

The following applications were processed through the Registry of Patents under section 115 of the Patents Order, 2011. Application numbers beginning with 'RP' are applications which were filed under the repealed Inventions Act (Cap 72) and were pending on 1 January 2012. Application numbers beginning with 'RE' are new re-registration applications filed after the implementation of the new Patents Order, 2011.

Date of filing:	17 February, 2020
Application No.:	RE/R/2020/0001
Patent No.:	EP2580236 B1 and US352461 P
Date of Grant:	8 June, 2011
Applicant (s)/Proprietor(s):	ASTRAZENECA AB and PIERIS PHARMACEUTICALS GMBH
Title:	TEAR LIPOCALIN MUTEINS BINDING IL-4 R ALPHA



FIRST SCHEDULE

FEES PAYABLE

<u>Matter</u>	<u>Fee</u>	<u>Corresponding Form(s)</u>
1. On filing a request for the grant of a patent	\$160.00	1
2. On reference under section 20(1) or 48(1)	\$450.00	2
3. On filing a counter-statement in each of the following cases –	\$40.00	3
(a) Opposing the making of an order under section 20 or 48		
(b) Opposing a request under section 22		
(c) In respect of a reference under section 23(5)		
(d) Opposing an application under section 24		
(e) In answer to a notice of opposition under section 38		
(f) In answer to a notice of opposition under section 41		
(g) In respect of a reference under section 49(5)		
(h) In respect of an application under section 55(3)		
(i) In answer to a notice of opposition under section 56(7)		
(j) In respect of a reference under section 65(3)		
(k) On contesting an application under section 76 for declaration of non- infringement		
(l) On contesting an application under section 77 for revocation of a patent		
(m) In answer to a notice of opposition under section 104(2) to the correction of an error, clerical error or mistake		
4. On application under section 20(5) or 48(3) for authorization by Registrar	\$50.00	4
5. On request for directions under section 22	\$450.00	5

6. On reference under section 23(5) or 49(5) to determine the question of licence	\$450.00	6
7. On application to the Registrar under section 24(1) 450 7 and/or 24(3)	\$450.00	7
8. On filing a statement of inventorship and of right to the grant of a patent	-	8
9. On request for early publication under section 27(2)	\$50.00	9
10. On filing a notice of withdrawal of an application for a patent under section 27(1)	-	10
11. On filing a request for a search report or a supplementary search report	\$1750.00	11
12. On filing a request for a search and examination report	\$2600.00	12
13. On furnishing information referred to in rule 46(1)	-	14
14. On filing a notice of intention to rely on an international preliminary report on patentability	-	15
15. On filing a request for an examination report	\$1100.00	16
16. On request to amend application before grant	-	17
17. On filing a response to a written opinion under section 31 or 39	-	18
18. On request that a certificate of grant be issued –		19
(a) where the application for a patent has not more than 25 claims in the patent specification when rule 49(3) is complied with	\$200.00	
(b) where the application for a patent has more than 25 claims in the patent specification when rule 49(3) is complied with	\$200.00 plus \$20.00 for Each claim in excess of 25 claims	
19. On payment of renewal fee (not including payment of back renewal fees pursuant to restoration or cancellation of entry in the register that licences are available as of right)	-	20

(a) for each year in respect of the 5th, 6th or 7th year of the patent		
(b) for each year in respect of the 8th, 9th or 10th year of the patent	\$160.00	
(c) for each year in respect of the 11th, 12th or 13th year of the patent	\$270.00	
(d) for each year in respect of the 14th, 15th or 16th year of the patent	\$350.00	
(e) for each year in respect of the 17th, 18th or 19th year of the patent	\$450.00	
(f) for the 20th year of the patent	\$550.00	
(g) for each year after the 20th year of the patent	\$650.00	
	\$950.00	
20. On payment of an additional fee for renewal under section 35(3) –		21
(a) not exceeding one month	\$50.00	
(b) each succeeding month (but not exceeding 6 months)	\$100.00	
21. On application to amend specification after grant	\$100.00	22
22. On notice of opposition to amendment of specification after grant	\$480.00	23
23. On application for the restoration of a patent	\$500.00	24
24. On payment of additional fee on the application for the restoration of a patent	\$300.00	25
25. On filing an offer to surrender a patent	\$70.00	26
26. On notice of opposition to offer to surrender a patent	\$250.00	27
27. On application to register or give notice of a transaction, instrument or event affecting the rights in a patent or an application for a patent – for each patent or application for a patent affected by such transaction, instrument or event	\$70.00	29
28. On filing a request, in respect of one or more patents or applications for patents, for –	\$12.00	28
(a) each alteration or correction of name		



(b) each alteration or correction of address (not being an address for service)

29. On filing a request, in respect of each patent or application for a patent, for –

(a) each alteration or correction of address for service

(b) each correction of an error in the register or any connected document

(c) each correction of an error of translation or transcript or clerical error or mistake in the specification of a patent, in an application for a patent or in any document filed in connection with a patent or such an application

30. On request for the furnishing of or access to miscellaneous information –

(a) fee for inspecting each file or document relating to a patent or patent application

\$6.50

(b) fee for furnishing each file or document

\$6.00

(c) fee for photocopying each page or part thereof of any other document by the staff of the Registry

\$0.30

(d) where the document is placed in the public search room

–

(i) fee for self-service photocopying of each page or part of the document using a stored-value card

\$0.15

(ii) fee for photocopying of each page or part thereof by the staff of the Registry

\$0.30

31. On request for certificate of the Registrar –

(a) by impressed stamp -

(i) for the first 20 sheets

\$18.00

(ii) for each additional sheet thereafter

\$0.30

(b) sealed and attached to the documents -

(i) for the first 20 sheets

\$30.00

(ii) for each additional sheet thereafter	\$0.30	
(c) in respect of a priority document under rule 17.1(b) of the Regulations under the Patent Cooperation Treaty	\$50.00	
(d) in respect of a certified copy of the international application for a patent under rule 124	\$28.00	
32. On application for entry of order of court in the register	\$10.00	32
33. On application by proprietor for entry to be made in the register to the effect that licences under the patent are to be available as of right	\$70.00	33
34. On application for settlement of terms of licence of right	\$380.00	34
35. On application under section 56(1) or section 56(3) for cancellation of entry in the register	\$70.00	35
36. On notice of opposition to an application under section 56(1) or 56(3) for cancellation of entry in the register	\$90.00	36
37. On reference to the Registrar of a dispute as to infringement	\$280.00	37
38. On application for declaration of non- infringement	\$280.00	38
39. On application under section 77 for the revocation of a patent	\$500.00	40
40. On request for re-examination of a patent in response to the Registrar's direction	\$900.00	41
41. On request for re-examination of a patent in response to the Registrar's direction	\$160.00	42
42. On payment of prescribed fee and request for publication of translation	\$70.00	43
43. On application to Registrar for an international application for a patent (Brunei Darussalam) to be treated as an application under the Order	\$160.00	44
44. On request for the exercise of the discretionary powers of the Registrar	\$100.00	48

45. On declaration of authorisation where agent appointed or in substitution for another	\$10.00 for each patent or application for patent	46
46. On payment of the advertisement fee upon receipt of the Registrar's request under rule 97(4)	\$18.00	47
47. On notice of opposition to the correction of an error, clerical error or mistake	\$100.00	48
48. On request for information relating to a patent or an application for a patent	\$24.00	49
49. On request for extension of each time or period under rule 114(4) - for each month or part of a month for which the extension is sought	\$200.00	50
50. On request for extension of each time or period under rule 114(6)	\$200.00	52
51. On payment of additional fee for extension of each time or period under rule 114(9) – for each month, or part of a month, for which the extension is granted	\$200.00	53
52. On request for extension of periods under sections 51 29(7) and 30(1)(a) – (a) where the application is not an international application for a patent (Brunel Darussalam) that has entered the national phase in Brunei Darussalam under section 83(3)	\$1800.00	
(b) where the application is an international application for patent (Brunei Darussalam) that has entered the national phase in Brunei Darussalam under section 83(3)	Nil	
53. On payment of transmittal fee under rule 14 of the Regulations under the Patent Co-operation Treaty	\$150.00	54
54. On payment of fee under rule 123(6) in respect of a request under rule 26 bis.3(a) of the Regulations under the Patent Co-operation Treaty	\$250.00	-



55. On request for certificate authorising release of sample of micro-organism	\$15.00	55
56. On notice of intention to restrict availability of samples of micro-organisms to experts	\$15.00	56
57. On request for certificate authorising release of sample of micro-organism to an expert	\$15.00	57
58. On payment of renewal fee under section 55 or 56 –		58
(a) for each year in respect of the 5th, 6th or 7th year of the patent	\$80.00	
(b) for each year in respect of the 8th, 9th or 10th year of the patent	\$135.00	
(c) for each year in respect of the 11th, 12th or 13th year of the patent	\$175.00	
(d) for each year in respect of the 14th, 15th or 16th year of the patent	\$225.00	
(e) for each year in respect of the 17th, 18th or 19th year of the patent	\$275.00	
(f) for the 20th year of the patent	\$325.00	
(g) for each year after the 20th year of the patent	\$475.00	
59. On application to extend the term of a patent under section 36	\$950.00	59
60. On filing a request for a search and examination report 60 after grant under section 39 –		60
(a) where the Examiner is the Austrian Patent Office	\$2680.00	
(b) where the Examiner is the Danish Patent and Trademark Office	\$3100.00	
(c) where the Examiner is the Hungarian Patent Office	\$2680.00	
61. On filing one or more documents under section 26(7)(c) or (8) or 28(8)	-	61

62. On filing a declaration under rule 9(2) or a request under rule 9(3)	\$120.00	62
63. On filing a request under rule 10(2)	\$250.00	62
64. On filing any miscellaneous document or documents	-	99
65. For using the patent computer facilities in the public search room of the Registry		
(a) for every half hour or part thereof of log on 2 access using the patent search terminal	\$2.00	
(b) for each sheet of information printed	\$0.30	
66. Purchase of a copy of —		
(a) Patents Journal A	\$10.00	
(b) Patents Journal B	\$36.00	



SECOND SCHEDULE

DESCRIPTIONS OF FORMS

<u>No.</u>	<u>Description of Form</u>	<u>Corresponding Form No.</u>
1	Certificate of Grant	Certificate Form 1
2	Certificate of Extension of Patent Term	Certificate Form 2
3	Request for the Grant of a Patent under section 25	Patents Form 1
4	Reference under section 20(1) or 48(1)	Patents Form 2
5	Counter statement	Patents Form 3
6	Application under section 20(5) or 48(3) for Authorisation by the Registrar	Patents Form 4
7	Request for Directions under section 22	Patents Form 5
8	Reference under section 23(5) or 48(5) to Determine the Question of a Licence	Patents Form 6
9	Application to Registrar under section 24(1) and/or 24(3)	Patents Form 7
10	Statement of Inventorship and of Right to the Grant of a Patent under section 24	Patents Form 8
11	Request for Early Publication under section 27(2)	Patents Form 9
12	Withdrawal of an Application for a Patent under section 27(1)	Patents Form 10
13	Request for a Search Report or Supplementary Search Report	Patents Form 11
14	Request for a Search and Examination Report	Patents Form 12
15	Furnishing of Prescribed Details	Patents Form 13
16	Furnishing of Prescribed Information	Patents Form 14
17	Notice of Intention to Rely on International Preliminary Report on Patentability under section 29(2)(e)(ii)	Patents Form 15
18	Request for an Examination Report	Patents Form 16
19	Request to Amend Application before Grant under section 31(2)	Patents Form 17



20	Response to Written Opinion under section 31 or 39	Patents Form 18
21	Payment of Fee for Grant of a Patent under section 30	Patents Form 19
22	Payment of Renewal Fee under section 35(2) or 56(2)	Patents Form 20
23	Payment of Additional Fee under section 35(3)	Patents Form 21
24	Application to Amend Specification after Grant under section 38	Patents Form 22
25	Notice of Opposition to Amendment of Specification after Grant under section 38 or 80	Patents Form 23
26	Application for Restoration of a Patent under section 40	Patents Form 24
27	Additional Fee on the Application for Restoration of a Patent under section 40	Patents Form 25
28	Offer to Surrender a Patent under section 41(1)	Patents Form 26
29	Notice of Opposition to Offer to Surrender a Patent under section 41(2)	Patents Form 27
30	Request for Alteration of Name, Address or Address for Service, or Correction of an Error, Clerical Error or Mistake under section 104	Patents Form 28
31	Application to Register or to Give Notice of a Transaction, Instrument or Event Affecting the Rights in a Patent or an Application for a Patent under section 44	Patents Form 29
32	Request for Miscellaneous Information under section 43 or 105	Patents Form 30
33	Request for Certificate of the Registrar under section 46	Patents Form 31
34	Application for Entry of Order of Court in the Register under section 44	Patents Form 32
35	Application for Entry to be Made in the Register to the effect that Licences under the Patent are to be available as of Right under section 55(1)	Patents Form 33
36	Application for Settlement of Terms of a Licence of Right under section 55(3)	Patents Form 34
37	Application under section 56(1) or (3) for Cancellation of Entry in the Register	Patents Form 35
38	Notice of Opposition to an Application under section 56(1) or (3) for Cancellation of Entry in the Register	Patents Form 36



39	Reference to the Registrar of a Dispute as to Infringement under section 65(3)	Patents Form 37
40	Application for Declaration of Non-Infringement under section 76	Patents Form 38
41	Application for Information on Corresponding Applications for a Patent	Patents Form 39
42	Application for Revocation of a Patent under section 77	Patents Form 40
43	Request for Re-Examination of a Patent in Response to direction of the Registrar under section 77	Patents Form 41
44	Payment of Fee for Entry into National Phase under section 83(3)	Patents Form 42
45	Payment of Prescribed Fee and Request for Publication of Translation under section 83(7)	Patents Form 43
46	Application to the Registrar for an International Application to be Treated as an Application under section 82 of the Order	Patents Form 44
47	Request for the Exercise of the Registrar's Discretionary Powers under section 89	Patents Form 45
48	Declaration of Authorisation where an Agent is Appointed or where One Agent is Substituted for Another	Patents Form 46
49	Additional Fee for the Advertisement of Proposed Correction under section 104	Patents Form 47
50	Notice of Opposition to the Correction of an Error, Clerical Error or Mistake under section 104	Patents Form 48
51	Request for Information Relating to a Patent or an Application for a Patent under section 105	Patents Form 49
52	Request for Extension of Time or Period under rule 114(4)	Patents Form 50
53	Request for Extension of Periods under sections 29 (7) and 30(1)(a)	Patents Form 51
54	Request for Extension of Time or Period under rule 114(6)	Patents Form 52
55	Additional Fee for Extension of Time or Period under rule 114(9)	Patents Form 53



56	Payment of Transmittal Fee under rule 14 of the Regulations under the Patent Co-Operation Treaty	Patents Form 54
57	Request for Certificate Authorising Release of Sample of Micro-Organism	Patents Form 55
58	Notice of Intention to Restrict Availability of Samples of Micro-Organisms to Experts	Patents Form 56
59	Request for Certificate Authorising Release of Sample of Micro-Organisms to an Expert	Patents Form 57
60	Payment of Renewal Fee pursuant to section 55(3)(d)	Patents Form 58
61	Request for an Extension of the Term of a Patent under section 36	Patents Form 59
62	Request for Search and Examination after Grant under section 39	Patents Form 60
63	Filing of Documents under section 26(7)(c) or (8) or 28(8)	Patents Form 61
64	Declaration under rule 9(2) or Request under rule 9(3) or 10(2)	Patents Form 62
65	Filing of Miscellaneous Document or Documents	Patents Form 99



THIRD SCHEDULE

SCALE OF COSTS

PART I

BASIC COST

<i>Item</i>	<i>Matter</i>	<i>Amount</i>
1	Drawing and filing notice of opposition or application for revocation together with statement of case	\$200.00
2	Drawing and filing a counter-statement	\$150.00
3	Preparing and lodging evidence for a notice of opposition, an application for revocation or a counter-statement	\$200.00 - \$800.00
4	Perusing a notice of opposition, an application for revocation or a counter-statement (per folio)	\$2.00 per folio
5	Preparing for all interlocutory proceedings	\$25.00 - \$120.00
6	Attending all interlocutory proceedings	\$25.00 - \$50.00
7	Preparing for hearing	\$500.00 - \$1500.00
8	Attendance at hearing by patent agent without advocate or solicitor	\$100.00 per hour up to a maximum of \$450.00 per day
9	Attendance at hearing by patent agent with instructing advocate or solicitor	\$60.00 per hour up to a maximum of \$270.00 per day
10	Advocate or Solicitor fees	\$120.00 per hour up to a maximum of \$540.00 per day
11	Drawing bill of costs (per folio)	\$2.00 per folio
12	Attending taxation, and obtaining the Registrar's certificate or order	\$50.00 - \$120.00



PART II

ADDITIONAL COSTS

1. A person who has paid a fee prescribed in these Rules in relation to proceedings before the Registrar shall be paid the amount of the fee.
2. A person attending proceedings before the Registrar shall be paid –
 - (a) a reasonable amount for expenses incurred for transport between the usual place of residence of the person and the place that he attends for that purpose; and
 - (b) if the person is required to be absent overnight from his usual place of residence, a reasonable amount as allowances up to a daily maximum of \$250 for meals and accommodation.
3. A person who, because of his professional, scientific or other special skill or knowledge, is summoned to appear before the Registrar as a witness shall be paid –
 - (a) if the person is remunerated in his occupation by wages, salary or fees, an amount equal to the amount of wages, salary or fees not paid to the person because of his attendance before the Registrar for that purpose, but such amount should not exceed \$150 per day; or
 - (b) in any other case, an amount of not less than \$100 but not more than \$150 for each day on which he so attends.



FOURTH SCHEDULE

MICRO-ORGANISMS

Applications.

1. (1) The specification of an application for a patent, or of a patent, for an invention which requires for its performance the use of a micro-organism –

- (a) which is not available to the public at the date of filing of the application; and
- (b) which cannot be described in the specification in such a manner as to enable the invention to be performed by a person skilled in the art, shall, in relation to the micro-organism itself, be treated for the purposes of the Order as disclosing the invention in such a manner only if one of the conditions set out in subparagraph (2), is satisfied.

(2) The conditions referred to in sub-paragraph (1) are –

- (a) a condition that –
 - (i) not later than the date of filing of the application, a culture of the micro-organism has been deposited with any international depositary authority which is able to furnish a sample of the micro-organism; and
 - (ii) the name of the international depositary authority, the date when the culture was deposited and the accession number of the deposit are given in the specification of the application; and
- (b) a condition, in the case of an international application for a patent (Brunei Darussalam) which is treated, by virtue of section 85 as a patent under the Order, or, as the case may be, an application for a patent under the Order, that the corresponding provisions of the Implementing Regulations to the Patent Co-operation Treaty have been complied with, and where a new deposit is made under paragraph 4, a further condition that the applicant or proprietor makes a new deposit in accordance with that paragraph.

(3) Where the condition of sub-paragraph (2)(a)(ii) is not satisfied at the time the application for a patent is filed, it shall be satisfied –

- (a) within 16 months from –
 - (i) the declared priority date; or
 - (ii) the date of filing the application where there is no declared priority date;
- (b) where, on a request made by the applicant, the Registrar publishes the application before the end of the period prescribed for the purposes of section 27(1), before the



date of the request; or

- (c) where the Registrar sends notification to the applicant that, in accordance with section 105(4), he has received a request by any person for information and inspection of documents under subsection (1) of that section, before the end of one month after his sending to the applicant notification of his receipt of the request, whichever is the earliest.
- (4) The giving of the information specified in sub-paragraph (2)(a)(ii) shall constitute the unreserved and irrecoverable consent of the applicant to the international depositary authority with which a culture (including a deposit which is to be treated as having always been available by virtue of paragraph 4(2)) is from time to time deposited making the culture available on receipt of the Registrar's certificate authorising the release to the person who is named therein as a person to whom the culture may be made available and who makes a valid request therefor to the authority.

Availability of cultures.

- 2. (1) Subject to paragraph 3, a request that the Registrar certify a person as a person to whom an international depositary authority may furnish a sample of a micro-organism –
 - (a) before publication of the application for a patent, to a person who has made a request under section 105(1) in the circumstances mentioned in paragraph 1(3)(c); and
 - (b) at any later time, to any person, shall be made on Patents Form 55 together with the form provided for by the Regulations under the Budapest Treaty.
- (2) The Registrar shall send a copy of any form lodged with him under subparagraph (1) and of his certificate authorising the release of the sample –
 - (a) to the applicant for, or proprietor of, the patent;
 - (b) to the international depositary authority; and (c) to the person making the request.
- (3) A request under sub-paragraph (1) shall comprise, on the part of the person to whom the request relates, undertakings for the benefit of the applicant for, or proprietor of, the patent –
 - (a) not to make the culture, or any culture derived from it, available to any other person; and
 - (b) not to use the culture, or any culture derived from it, otherwise than for experimental purposes relating to the subject matter of the invention, and –
 - (i) subject to sub-paragraph (iii), both undertakings shall have effect during any period before the application for a patent has been withdrawn, has been treated as having been abandoned, has been refused or is treated as having been refused (including any further period allowed under rule 110, 120(1) or (6) but excluding,



where an application is reinstated under either of those rules, the period before it is reinstated);

- (ii) if a patent is granted on the application, the undertaking set out in sub-paragraph (a) shall also have effect during any period for which the patent is in force and during the period of 6 months referred to in section 35(3); and
- (iii) the undertaking set out in sub-paragraph (b) shall not have effect after the date of publication in the journal of a notice that the patent has been granted, and, in this sub-paragraph, references to a culture derived from a deposited culture of a microorganism are references to a culture so derived which exhibits those characteristics of the deposited culture essential for the performance of the invention.

(4) For the purpose of enabling any act specified in section 59 to be done in relation to the culture for the services of the Government, the undertakings specified in subparagraph (3) –

- (a) shall not be required from any Government department or person authorised in writing by a Government department for the purposes of this paragraph; and
- (b) shall not have effect in relation to any such person who has already given them.

(5) An undertaking given pursuant to sub-paragraph (3) may be varied by way of derogation by agreement between the applicant or proprietor and the person by whom it is given.

(6) Where, in respect of a patent to which the undertaking set out in sub-paragraph (3)(a) has effect –

- (a) an entry is made in the register under section 55 to the effect that licences are to be available as of right; or
- (b) a compulsory licence is granted under section 57, that undertaking shall not have effect to the extent necessary for effect to be given to any such licence.

Availability of cultures to experts.

3. (1) Subject to sub-paragraph (3), where, before the preparations for publication under section 27 of an application for a patent have been completed, the applicant gives notice to the Registrar on Patents Form 56 of his intention that a sample of the microorganism should be made available only to an expert, the provisions of this paragraph shall have effect.

(2) The Registrar –

- (a) shall, at the time of publication of the application under section 27, publish a notice in the journal that the provisions of this paragraph have effect; and
- (b) notwithstanding paragraph 2, shall not, until the patent is granted or the application has been withdrawn, has been treated as having been abandoned, has been refused or is



treated as having been refused, issue any certificate authorising release of a sample otherwise than under this paragraph.

(3) In the case of an international application for a patent (Brunei Darussalam), the applicant may, for the purpose set out in sub-paragraph (1), give notice in writing to the International Bureau under rule 13 bis 3 of the Regulations under the Patent Co-operation Treaty before the technical preparations for international publication of the application are complete of his intention that a sample of the micro-organism should be made available only to an expert and he shall be treated by the Registrar for the purposes of this paragraph as having complied with the conditions in sub-paragraph (1) and sub-paragraph (2)(a) shall not apply.

(4) Any person wishing to have a sample of the micro-organism made available ("the requester") –

(a) shall apply to the Registrar on Patents Form 57 together with the form provided for by the Regulations under the Patent Co-operation Treaty nominating the person ("the expert") to whom he wishes the sample to be made available; and

(b) shall at the same time file undertakings by the expert as set out in paragraph 2 (3) in accordance with the provisions of that paragraph.

(5) The Registrar shall send a copy of Patents Form 57 filed under sub-paragraph (4) to the applicant for the patent and shall specify the period within which the applicant may object, in accordance with sub-paragraph (6), to a sample of the micro-organism being available to the expert.

(6) Unless, within the period specified by the Registrar under sub-paragraph (5) (or within such longer period as the Registrar may, on application made to him within that period, allow), the applicant for the patent sends notice in writing to the Registrar that he objects to a sample of the micro-organism being made available to the expert and gives his reasons for his objection, the Registrar shall send a copy of any form lodged with him under sub-paragraph (4)(a) and of his certificate authorising the release of the sample –

(a) to the applicant for the patent;
(b) to the international depositary authority concerned;
(c) to the requester; and
(d) to the expert.

(7) Where, in accordance with sub-paragraph (6), the applicant for the patent sends notice to the Registrar of his objection to the issue of a certificate in favour of the expert, the Registrar –

(a) shall decide, having regard to the knowledge, experience and technical qualifications of the expert and to any other factors he considers relevant, whether to issue his certificate in favour of the expert; and

(b) if he decides to authorise the release of the sample to the expert, shall send to the persons



referred to in sub-paragraph (6) a copy of any form lodged with him under subparagraph (4)(a) and of his certificate authorising the release of the sample to the expert.

(8) Before making a decision in accordance with sub-paragraph (7), the Registrar shall afford the applicant and the requester the opportunity of being heard.

(9) If the Registrar decides under sub-paragraph (7) not to issue his certificate in favour of the expert, the requester may, by notice in writing to the Registrar and the applicant, nominate another person as the expert for the purposes of this paragraph; and the Registrar shall give such directions as he may think fit with regard to the subsequent procedure.

(10) Nothing in this paragraph shall affect the rights under section 58 of any Government department or of any person authorised in writing by a Government department.

New deposits.

4. (1) Where the international depositary authority with which a deposit or a new deposit of a culture has been made under this Schedule –

(a) notifies the applicant or proprietor that it –

(i) cannot satisfy a request made in accordance with paragraph 2(1) or 3(4); or

(ii) is not able lawfully, to satisfy such a request, for the culture to be made available;

(b) ceases temporarily or permanently to carry out the functions of an international depositary authority; or

(c) ceases for any reason to conduct its activities as an international depositary authority in an objective and impartial manner, subject to sub-paragraph (3), the applicant or proprietor may, unless the culture has been transferred to another international depositary authority which is able to make it available, make a new deposit of a culture of the micro-organism.

(2) For the purposes of paragraph 1 and this paragraph, the deposit shall be treated as always having been available if, within 3 months of the receipt of such notification or of the international depositary authority ceasing to perform the functions of an international depositary authority or to conduct its activities as such an authority in an objective and impartial manner, the applicant or proprietor –

(a) in a case where the deposit has not already been transferred, makes the new deposit;

(b) furnishes to the international depositary authority with which the new deposit is made a declaration that the culture so deposited is of the same microorganism as was the culture originally deposited; and



(c) requests amendment of the specification under section 31 or 38, as the case may be, so as to indicate the accession number of the transferred or new deposit and, where applicable, the name of the international depositary authority with which the deposit has been made.

(3) The new deposit referred to in sub-paragraph (1) –

(a) shall, subject to sub-paragraph (b), be made with the same international depositary authority as was the original deposit; or

(b) in the cases referred to in sub-paragraphs (1)(a)(ii), (b) and (c), shall be made with another international depositary authority which is able to satisfy the request.

Interpretation.

5. In this Schedule –

"Budapest Treaty" means the Treaty on the International Recognition of the Deposit of Microorganisms for the purposes of Patent Procedure done at Budapest in 1977; "depositary institution" means an institution which, at all relevant times –

(a) carries out the functions of receiving, accepting and storing microorganisms and the furnishing of samples thereof; and

(b) conducts its affairs in so far as they relate to the carrying out of those functions in an objective and impartial manner;

"international depositary authority" means a depositary institution which has acquired the status of international depositary authority as provided in Article 7 of the Budapest Treaty.



FIFTH SCHEDULE

REMUNERATION OF SCIENTIFIC ADVISERS

1. A person appointed as a scientific adviser to assist the Registrar in proceedings under the Order and who attends the proceedings before the Registrar shall be paid –
 - (a) a reasonable amount for expenses incurred for transport between his usual place of residence and the place where the proceedings take place; and
 - (b) if the scientific adviser is required to be absent overnight from his usual place of residence, a reasonable amount as allowance for meals and accommodation up to a daily maximum of \$250.
2. A person appointed as a scientific adviser to assist the Registrar in proceedings under the Order shall, apart from the expenses and allowances referred to in paragraph 1, be paid an amount of not less than \$650 but not more than \$2,000 for each day or part thereof for which he hears the case or works on the report pursuant to an inquiry referred to him under rule 119(1)(b).
3. A person appointed as a scientific adviser to sit with the Registrar at the hearing of any proceedings may, apart from the expenses and allowances referred to in paragraph 1, be paid an amount not less than \$650 but not more than \$2,000 if he is subsequently not required to hear the proceedings with the Registrar.



**REGISTRAR OF PATENT
BRUNEI DARUSSALAM**

PATENTS RULES [S 11/2013]

NEW PATENT APPLICATION

[21] BN/N/2022/0035 [22] 03/03/2020

[54] **RIP1 Inhibitory Compounds And Methods For Making And Using The Same**

[71] **RIGEL PHARMACEUTICALS, INC. of 1180 Veterans Boulevard, South San Francisco, California 94080, United States of America**

[72] **1. CHEN, YAN
2. YU, JIAJIN
3. SHAW, SIMON
4. DARWISH, IHAB
5. TAYLOR, VANESSA
6. BHAMIDIPATI, SOMASEKHAR
7. LUO, ZHUSHOU
8. KOLLURI, RAO**

[74] **Messrs. SPRUSON & FERGUSON PTE LTD of AIP Law, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]

No. US62/897,223 Date: 06 September 2019 Country: United States of America

No. US62/932,404 Date: 07 November 2019 Country: United States of America

No. US63/001,016 Date: 27 March 2020 Country: United States of America

No. US63/004,290 Date: 02 April 2020 Country: United States of America

No. US63/004,319 Date: 02 April 2020 Country: United States of America

[86] PCT/US2020/049527

[87] WO/2021/046437

[51] C07D 471/04, C07D 487/04, A61K 31/55, A61P 37/00

[57] Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.



[21] BN/N/2022/0036 [22] 05/03/2020

[54] **RIP1 Inhibitory Compounds And Methods For Making And Using The Same**

[71] **RIGEL PHARMACEUTICALS, INC. of 1180 Veterans Boulevard, South San Francisco, California 94080, United States of America**

[72] **1. CHEN, YAN
2. YU, JIAJIN
3. SHAW, SIMON
4. DARWISH, IHAB
5. TAYLOR, VANESSA
6. BHAMIDIPATI, SOMASEKHAR
7. LUO, ZHUSHOU
8. KOLLURI, RAO**

[74] **Messrs. SPRUSON & FERGUSON PTE LTD., c/o AIP Law, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]

No. US62/897,223 Date: 06 September 2019 Country: United States of America
No. US62/932,404 Date: 07 November 2019 Country: United States of America
No. US63/001,016 Date: 27 March 2020 Country: United States of America
No. US63/004,290 Date: 02 April 2020 Country: United States of America
No. US63/004,301 Date: 02 April 2020 Country: United States of America
No. US63/004,319 Date: 02 April 2020 Country: United States of America

[86] PCT/US2020/049487

[87] WO/2021/046407

[51] C07D 413/14, C07D 413/12, A61P 37/00, A61K 31/553

[57] Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.

[21] BN/N/2022/0037 [22] 07/03/2022

[54] **A Device For Measuring Jaundice Levels**



[71] RECOVE GROUP SDN. BHD. of TGB-09, Block B, PUSTEK 2, UKM-MTDC Technology Centre, Universiti Kebangsaan Malaysia, 43600 Bangi, Selangor, Malaysia

[72] 1. DUL RAHMAN BIN BAHASA
2. MUHAMMAD KHAIRIL BIN ZAINUDIN
3. REIMEI IKHSAN BIN MOHD RASIT

[74] Messrs. PINTAS IP GROUP SDN BHD, No.4, Spg 538-37-3, Kg Sg Akar, Jln Kebangsaan Lama, BC4115, Bandar Seri Begawan BE1318, Brunei Darussalam

[51] A61B 5/1455

[57] The present invention discloses a device (1) for measuring jaundice levels, the device (1) comprising a body (2) accommodating a light transmitting means (6) for emitting light at a predetermined wavelength, a light receiving means for receiving reflected light, means to activate the device (1) so that upon contact between the device (1) and a surface of a target area, light is emitted and received by the device (1), in which the received light is processed by a means for determining jaundice levels, wherein said means for determining jaundice levels is incorporated with a means for transmitting information elsewhere from the device (1)




FIG. 1

[21] BN/N/2022/0038 [22] 07/03/2022

[54] Electrolysis System And Method

[71] ENERGYNE PTY LTD of PO Box 5184, Murwillumbah South, New South Wales 2484, Australia

[72] 1. CAMPEANU, Ron
2. CAMPEANU, Thomas

[74] Messr. MIRANDAH ASIA SDN BHD c/o AIP LAW of Unit Nos. 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan, BS8811, Brunei Darussalam




[31][32][33]
No. AU2019903244 Date: 03 September 2019 Country: Australia

[86] PCT/AU2020/050906

[87] WO/2021/042158

[51] C25B 1/04, C25B 15/02

[57] An electrolysis system, comprising a power supply configured to provide an input voltage; and a controller configured to receive the input voltage and output a pulse width modulated voltage, the output voltage being a 30V square wave having a variable duty cycle in the range of 1% to 10%. The system further comprises at least one electrolysis cell configured to receive the output voltage, each electrolysis cell comprising a plurality of metal plates, each electrolysis cell being configured for receiving water containing an electrolyte to split the water when the output voltage is received.



[21] BN/N/2022/0039 [22] 10/03/2022

[54] Method For Producing Propene And Low-Sulfur Fuel Oil Component

[71] CHINA PETROLEUM & CHEMICAL CORPORATION of 22 Chaoyangmen North Street, Chaoyang District, Beijing 100728, China
RESEARCH INSTITUTE OF PETROLEUM PROCESSING, Sinopec Of 18 Xueyuan Road, Haidian District, Beijing 100083, China

[72] 1. XU, YOUEAO
2. BAI, XUHUI
3. XIE, XINYU
4. CUI, SHOUYE
5. WANG, XIN
6. ZUO, YANFEN

[74] Messrs. HENRY GOH & CO. SDN. BHD., c/o AIP LAW of Unit 405A-410A 4th Floor,

Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan, BS8811, Brunei Darussalam

[31][32][33]

No. CN201911014995.6 Date: 24 October 2019 Country: China

[86] PCT/CN2020/121012

[87] WO/2021/078052

[51] C07C 11/06, C10G 67/04, C10G 69/04

[57] A method for producing propene and a low-sulfur fuel oil component, comprising: making heavy feedstock oil contact a solvent, performing extraction and separation to obtain deasphalted oil and deoiled asphalt, and making the deasphalted oil and optional light feedstock oil contact and react with a catalytic conversion catalyst to obtain a propylene-containing reaction product; and separating a catalytically cracked distillate from the reaction product, and enabling hydrodesulfurization of the catalytically cracked distillate to obtain a low-sulfur hydrogenated distillate. The low-sulfur hydrogenated distillate and/or the deoiled asphalt serves as a fuel oil component. According to the method, a saturated hydrocarbon in heavy feedstock oil can be converted into propylene, thereby avoiding using the saturated hydrocarbon as a fuel oil component and achieving good economic and social benefits.




图 1

[21] BN/N/2022/0041

[22] 15/03/2022

[54] N4-Hydroxycytidine And Derivatives And Anti-Viral Uses Related Thereto

[71] EMORY UNIVERSITY of 1599 Clifton Road NE 4th Floor 30322, Atlanta, United States of America

[72] 1. PAINTER, GEORGE R.
2. BLUEMLING, GREGORY R.
3. NATCHUS, MICHAEL G.
4. MAO, SHULI
5. MARENGO, JOSE
6. HAGER, MICHAEL W.
7. PERRYMAN, DAVID



[74] **Messr. MIRANDAH ASIA SDN BHD c/o AIP LAW of Unit Nos. 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan, BS8811, Brunei Darussalam**

[31][32][33]

No. US62/971,559 Date: 07 February 2020 Country: United States of America

[86] PCT/US2021/016984

[87] WO/2021/159044

[51] A61K 31/7064, A61K 31/7068, A61P 31/12, C07H 19/04, C07H 19/06, C07H 19/067

[57] This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of human coronavirus 2019-nCoV.




FIG. 1

[21] BN/N/2022/0042 [22] 16/03/2022

[54] **Threaded Connection Including And Intermediate Shoulder**

[71] **NIPPON STEEL CORPORATION of 6-1, Marunouchi 2-chome, Chiyoda-ku, Tokyo, 1008071, Japan**
VALLOUREC OIL AND GAS FRANCE of 54 rue Anatole France, AULNOYE-AYMERIES 59620, France

[72] **1. FOTHERGILL, ALAN
2. DUFRENE, COREY
3. MARUTA, SATOSHI**

[74] **Messrs. HENRY GOH & CO. SDN. BHD., c/o AIP LAW of Unit 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan, BS8811, Brunei Darussalam**

[31][32][33]

No. EP19199254.4 Date: 24 September 2019 Country: European Patent Office


[86] PCT/EP2020/076430

[87] WO/2021/058481

[51] E21B 17/042


[57] A threaded tubular connection comprises a first tubular (12) component and a second tubular component (14). The first tubular component (12) includes a female portion (10) defined on an interior surface of the first tubular component. The female portion includes an inner threaded portion (16d) and an outer threaded portion (16b) which are offset radially with respect to a longitudinal axis of the first tubular component by a first shoulder (26). The second tubular component (14) includes a male portion (18) defined on an exterior surface of the second tubular component. The male portion is to be inserted into the female portion, and includes an inner threaded portion (18d) and an outer threaded portion (18b) which are offset radially with respect to a longitudinal axis of the second tubular component by a second shoulder (28). The second shoulder is to abut the first shoulder once the male portion is connected to the female portion. The threaded tubular connection comprises an inner short length fluid tight seal.

Fig. 1





adapted to slide longitudinally to a run-in position, in which the tubular sliding shroud is disposed about the jumper tube and respective portions of the first and second completion joints, thereby covering the jumper tube. A method and apparatus are also provided.



[21] BN/N/2022/0044

[22] 22/03/2022

[54] **Development Of A Novel Live Attenuated African Swine Fever Vaccine Based In The Deletion Of Gene I177l**

[71] **THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF ARGICULTURE of 1400 Independence Ave, S. W., Washington, District of Columbia 20250, United States of America**

[72] **1. GLADUE, DOUGLAS P.
2. BORCA, MANUEL V.**

[74] **Messrs. MIA MANAGEMENT SERVIES of Unit No. 18, Anggerik Desa Complex, Bandar Seri Begawan, BB3780, Brunei Darussalam**

[31][32][33]

No. US16/580,058 Date: 24 September 2019 Country: United States of America

[86] PCT/US2020/022569


[87] WO/2021/061189

[51] C12N 7/00, A61K 39/12, A61P 31/20, A61K 39/00

[57] **Provided herein are details on the construction of a recombinant African Swine Fever Virus (ASFV) live attenuated vaccine for prevention of ASF caused by various strains of ASFV, such as the highly virulent Georgia 2007 isolate ("ASFV-G"). An exemplary**



vaccine comprises the ASFV-GΔI177L modified virus, a recombinant ASFV-G modified by deleting a portion of the I177L ORF rendering the I177L gene nonfunctional.





[21] BN/N//2022/0047 [22] 05/04/2022

[54] Arylmethylene Heterocyclic Compounds As Kv1.3 Potassium Shaker Channel Blockers

[71] D. E. SHAW RESEARCH, LLC of 120 W. 45th Street 39th Floor, New York, New York 10036, United States of America

[72] 1. GIORDANETTO, FABRIZIO
2. JENSEN, MORTEN, ØSTERGAARD
3. JOGINI, VISHWANATH
4. SNOW, ROGER, JOHN

[74] Messrs. SPRUSON & FERGUSON PTE LTD of AIP Law, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam


[31][32][33]
No. US62/911,655 Date: 07 October 2019 Country: United States of America

[86] PCT/US2020/054352

[87] WO/2021/071806

[51] A61K 31/4245, A61K 31/433, A61K 45/06

[57] A compound of Formula (I) or a pharmaceutically acceptable salt thereof is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.



[21] BN/N/2022/0048 [22] 09/04/2022

[54] Process For Producing Light Olefins And Low-Sulfur Fuel Oil Components

[71] CHINA PETROLEUM & CHEMICAL CORPORATION of Chaoyang District, Beijing 100728, China
RESEARCH INSTITUTE OF PETROLEUM PROCESSING, Sinopec of 18 Xueyuan Road, Haidian District, Beijing 100083, China

[72] 1. XU, YOUHAO
2. WANG, XIN
3. ZUO, YANFEN
4. CUI, SHOUYE
5. BAI, XUHUI
6. XIE, XINYU

[74] **Messrs. HENRY GOH & CO. SDN. BHD.**, c/o AIP LAW of Unit 405A-410A 4th Floor,
Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan, BS8811, Brunei Darussalam


[31][32][33]
No. CN201911014993.7 Date: 24 October 2019 Country: China

[86] PCT/CN2020/121005

[87] WO/2021/078051

[51] C10G 11/00, C07C 11/06, C07C 4/06

[57] Provided is a method for producing propylene and low-sulfur fuel oil components, comprising the following steps: i) hydrocarbon-containing feedstock oil is contacted and reacted with a catalytic conversion catalyst under effective conditions in the absence of hydrogen in a catalytic conversion reactor to obtain a propylene-containing reaction product; ii) the catalytic cracking distillate oil is separated from the reaction product obtained in step i), and iii) the catalytic cracking distillate oil is hydrodesulfurized to obtain a low-sulfur hydrogenated distillate oil as a fuel oil component. The method can greatly increase the selectivity of propylene and the yield of propylene while producing more fuel oil components, and obviously reduce the yield of dry gas and coke, and has good economic and social benefits.



[21] BN/N/2022/0049 [22] 11/04/2022
[54] Oral Complement Factor D Inhibitors
[71] BIOCRYST PHARMACEUTICALS, INC. of 4505 Emperor Blvd., Suite 200 Durham,
North California 27703, United States of America



[72] 1. KOTIAN, PRAVIN, L.
 2. BABU, YARLAGADDA, S.
 3. ZHANG, WEIHE
 4. LU, PENG-CHENG
 5. SPAULDING, ANDREW, E.
 6. LV, WEI
 7. DANG, ZHAO
 8. RAMAN, KRISHNAN

[74] **Messr. MIRANDAH ASIA SDN BHD c/o AIP LAW of Unit Nos. 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan, BS8811, Brunei Darussalam**

[31][32][33]


No. US62/912,929 Date: 09 October 2019 Country: United States of America

[86] PCT/US2020/054992

[87] WO/2021/072198

[51] A61K 31/506, A61K 31/519, A61K 31/5377

[57] Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.



[21] BN/N/2022/0050

[22] 11/04/2022

[54] **Oral Complement Factor D Inhibitors**

[71] **BIOCRYST PHARMACEUTICALS, INC. of 4505 Emperor Blvd., Suite 200 Durham, North California 27703, United States of America**

[72] 1. KOTIAN, PRAVIN, L.
 2. BABU, YARLAGADDA, S.
 3. ZHANG, WEIHE
 4. LU, PENG-CHENG
 5. SPAULDING, ANDREW, E.
 6. LV, WEI



7. DANG, ZHAO
8. RAMAN, KRISHNAN

[74] **Messr. MIRANDAH ASIA SDN BHD c/o AIP LAW of Unit Nos. 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan, BS8811, Brunei Darussalam**

[31][32][33]

No. US62/913,021 Date: 09 October 2019 Country: United States of America

[86] **PCT/US2020/054922**

[87] **WO/2021/072156**

[51] **C07D 307/80, C07D 307/81, A61K 31/343**

[57] **Disclosed are compounds of formula (I)-(IV), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.**

[21] **BN/N/2022/0051** [22] **11/04/2022**

[54] **Dredging Method And Apparatus**

[71] **HARWICH HAVEN AUTHORITY of Navigation House Angel Gate
Harwich Essex, C012 3EJ, United Kingdom**

[72] **1. WARNER, JEREMY, DAVID**

[74] **Messr. MIRANDAH ASIA SDN BHD c/o AIP LAW of Unit Nos. 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan, BS8811, Brunei Darussalam**

[31][32][33]

No. GB1916776.6 Date: 18 November 2019 Country: United Kingdom

No. GB2007660.0 Date: 22 May 2020 Country: United Kingdom

[86] **PCT/EP2020/080155**

[87] **WO/2021/099074**

[51] **E02F 3/92**

[57] **A method of dredging which comprises suspending dredging apparatus 200 from a vehicle 360. The sediment agitating apparatus comprising a chassis 210, and mounted**



on the chassis are an extractor, sediment agitating apparatus and respective pumps 220, 230. The dredging apparatus 200 is disposed above, but not in contact with a waterbed 340 to be dredged of sediment 350. The sediment 350 is agitated then extracted with the extractor. The dredging apparatus 200 is moved around the water and the extracted sediment 400 is deposited underwater and above the dredging apparatus 200, so that the sediment 400 is transported and deposited away from an area being dredged by the natural movement of the water. Apparatus and use of the apparatus are also described.




Figure 12

[21]	BN/N/2022/0052	[22]	11/04/2022
------	----------------	------	------------

[54] **Inhibiting Human Integrin A4ß7**

[71] **MORPHIC THERAPEUTIC, INC. of 35 Gatehouse Drive, A2 Waltham, MA 02451, United States of America**

[72] **1. BURSAVICH, MATTHEW G.
2. CUI, DAN
3. DOWLING, JAMES E.
4. HAHN, KRISTOPHER N.
5. HARRISON, BRYCE A.
6. LIN, FU-YANG
7. LIPPA, BLAISE S.
8. ROGERS, BRUCE N.
9. TROAST, DAWN M.
10. ZHONG, CHENG
11. KONZE, KYLE D.
12. GERASYUTO, ALEKSEY I.
13. KIM, BYUNGCHAN
14. RAFI, SALMA
15. DAY, TYLER
16. HICKEY, EUGENE
17. HOUANG, EVELYNE
18. ZAHLER, ROBERT**

[74] **Messr. MIRANDAH ASIA SDN BHD c/o AIP LAW of Unit Nos. 405A-410A 4th Floor,**



Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan, BS8811, Brunei Darussalam

[31][32][33]


No. US62/916,062 Date: 16 October 2019 Country: United States of America

[86] PCT/US2020/055986

[87] WO/2021/076890

[51] A61K 31/4375, C07D 207/04, C07D 471/04

[57] Disclosed are small molecule antagonists of human $\alpha 4\beta 7$ integrin, and methods of using them to treat a number of diseases and conditions.



[21] BN/N/2022/0053

[22] 11/04/2022

[54] Bicyclic Heterocycles As Fgfr Inhibitors

[71] INCYTE CORPORATION of 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States of America

[72] 1. VECHORKIN, OLEG
2. NGUYEN, MINH
3. QI, CHAO
4. WANG, ANLAI
5. WITTEN, MICHAEL
6. YE, HAI FEN
7. ZHANG, KE
8. ZHAO, PENG
9. YAO, WENQING
10. XU, YAO

[74] AIP LAW of Unit 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan, BS8811, Brunei Darussalam

[31][32][33]

No. US62/914,766 Date: 14 October 2019 Country: United States of America

No. US63/004,972 Date: 03 April 2020 Country: United States of America




[86] PCT/US2020/055547

[87] WO/2021/076602

[51] A61P 35/00, C07D 471/04, A61K 31/437

[57] The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer. Formula (I).



[21] BN/N/2022/0054 [22] 11/04/2022

[54] Bicyclic Amines As CDK2 Inhibitors

[71] INCYTE CORPORATION of 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States of America

[72] 1. HUMMEL, JOSHUA
2. XU, MEIZHONG
3. YE, MIN
4. CHEN, YINGNAN
5. FAVATA, MARGARET
6. LO, YVONNE
7. YE, YINGDA
8. LI, ZHENWU
9. QIAN, DING-QUAN
10. WINTERTON, SARAH
11. XIAO, KAIJIONG
12. WU, LIANGXING
13. YAO, WENQING

[74] AIP LAW of Unit 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan, BS8811, Brunei Darussalam

[31][32][33]
No. US62/914,114 Date: 11 October 2019 Country: United States of America

[86] PCT/US2020/055033



[87] WO/2021/072232

[51] C07D 471/04, C07D 487/04, A61P 35/00, A61K 31/437, A61K 31/5025, A61K 31/519

[57] The present application provides bicyclic amines that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.

[21] BN/N/2022/0056 [22] 16/04/2022

[54] System And Method For Controlling Artificial Lift Units

[71] WEATHERFORD TECHNOLOGY HOLDINGS, LLC of 2000 St James Place, Houston, Texas 77056, United States of America

[72] 1. NIMBALKAR, MANOJ M
2. VENKATESH, BIMAL
3. ACKERMAN, RYAN S
4. CALDER, DEAN A

[74] Messrs. MARKS & CLERK SINGAPORE LLP c/o AIP LAW of Unit Nos. 404A-410A, 4th Floor, Wisma Jaya Jalan Pemancha, Bandar Seri Begawan, BS8811, Brunei Darussalam

[31][32][33]
No. US62/931,071 Date: 05 November 2019 Country: United States of America

[86] PCT/US2020/058261

[87] WO/2021/091792

[51] E21B 33/035, G06F 15/18

[57] A system and method controls a plurality of artificial lift units at a plurality of wellsites. Processing equipment installs at a plurality of the wellsites. Operating parameters of each of the artificial lift units are obtained with sensing equipment at the wellsites and are communicated in real-time from the wellsites to the installed processing equipment at the plurality of the wellsites. A modelling function of the processing equipment analyzes a trend of the operating parameters of the artificial lift units, and automated machine learning of the processing equipment predicts a condition of at least one of the artificial lift units based on the analyzed trend. The processing equipment determines at least one automated control for the determined condition of the at least one artificial lift unit and counters the determined condition by implementing the at least one automated control at the at least one artificial lift unit.




FIG. 8

[21] BN/N/2022/0057 [22] 16/04/2022

[54] Method For Producing Light Aromatic

[71] CHINA PETROLEUM & CHEMICAL CORPORATION of Chaoyang District, Beijing 100728, China
RESEARCH INSTITUTE OF PETROLEUM PROCESSING, Sinopec Of 18 Xueyuan Road, Haidian District, Beijing 100083, China

[72] 1. WANG, DI
2. WEI, XIAOLI
3. GONG, JIANHONG
4. YU, JINGCHUAN
5. ZHANG, JIUSHUN

[74] Messrs. HENRY GOH & CO. SDN. BHD., c/o AIP LAW of Unit 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan, BS8811, Brunei Darussalam

[31][32][33]
No. CN201911047207.3 Date: 30 October 2019 Country: China

[86] PCT/CN2020/106771

[87] WO/2021/082579

[51] C07C 15/02, C07C 15/08, C07C 15/04, B01J 29/00

[57] A method for producing a light aromatic, comprising: i) bringing a raw material containing a heavy aromatic into contact with a catalyst in a fluidized reactor, and carrying out an aromatic lightening reaction under hydrogen conditions to obtain products rich in C6-C8 light aromatics and a spent catalyst, wherein the heavy aromatic is selected from one or a plurality of C9+ aromatics; ii) separating the products rich in C6-C8 light aromatics to obtain hydrogen, non-aromatic components, C6-C8 light aromatics, and C9+ aromatic components; and iii) returning at least part of the C9+ aromatic components to the fluidized reactor. The method has strong adaptability to raw materials, flexible operation, and high flexibility, and can ensure



long-term stable operation. The method can produce high-value light aromatics by using heavy aromatics that are difficult to treat and utilize.




图 1

[21] BN/N/2022/0058 [22] 16/04/2022

[54] Method And System For Treating Catalytic Cracking Reaction Product, And Use Thereof

[71] CHINA PETROLEUM & CHEMICAL CORPORATION of Chaoyang District, Beijing 100728, China
RESEARCH INSTITUTE OF PETROLEUM PROCESSING, Sinopec Of 18 Xueyuan Road, Haidian District, Beijing 100083, China

[72] 1. WANG, DI
2. WEI, XIAOLI
3. GONG, JIANHONG
4. YU, JINGCHUAN
5. ZHANG, JIUSHUN

[74] Messrs. HENRY GOH & CO. SDN. BHD., c/o AIP LAW of Unit 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan, BS8811, Brunei Darussalam

[31][32][33]
No. CN201911048194.1 Date: 30 October 2019 Country: China

[86] PCT/CN2020/106745

[87] WO/2021/082578

[51] C10G 61/04, C10G 63/08

[57] Disclosed are a method and a system for treating catalytic cracking gasoline, and a process and a device for catalytic cracking. The method and system use a fluidized reactor for hydrodealkylation treatment of a catalytic cracking reaction oil gas or catalytic cracking gasoline, such that heavy aromatic hydrocarbons contained therein are efficiently converted into low carbon olefins and light aromatic hydrocarbons. The



method and system can improve the yield of low carbon olefins, ensure long-term stable operation, and can alleviate the discrepancy between supply and demand of light aromatic hydrocarbons, which solves the problems of the content of aromatic hydrocarbons in a reaction oil gas of a catalytic cracking device being high, but there being many low-value heavy aromatic hydrocarbons which are difficult to utilize.




图 1

AA Other products

[21] BN/N/2022/0059 [22] 18/04/2022

[54] Fabrication Of Carbon Fibers With High Mechanical Properties

[71] TANGOLD INC. of Address 9407-3 20th Avenue NW Edmonton, Alberta T6N 1E5, CANADA

[72] 1. CHEN, WEIXING

[74] Messrs. PINTAS IP GROUP SDN BHD, No.4, Spg 538-37-3, Kg Sg Akar, Jln Kebangsaan Lama, BC4115, Bandar Seri Begawan BE1318, Brunei Darussalam

[31][32][33]
No. US62/916,680 Date: 17 October 2019 Country: United States of America
No. US62/925,672 Date: 24 October 2019 Country: United States of America

[86] PCT/CA/2020/051403

[87] WO/2021/072559

[51] D01F 9/12, C01B 32/00

[57] A method of fabricating carbon fibers includes the steps of: (a) melting asphaltene solids in a sealed vessel; (b) spinning melted asphaltenes to fabricate green fibers; (c) stabilizing the green fibers; (d) carbonizing the stabilized green fibers; and (e) optionally graphitizing carbonized fibers.




FIG.1



FIG. 2

[21] BN/N/2022/0060 [22] 20/04/2022

[54] **TREM2 Antigen Binding Proteins And Uses Thereof**

[71] **AMGEN INC. of One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, California 91320-1799, United States of America**

[72] **1. FOLTZ IAN
2. SHILPA SAMBASHIVAN
3. IRWIN CHEN
4. SUSIE MIKI HARRIS
5. DORA TOLEDO WARSHAVIAK
6. IAN DRIVER
7. DANIEL LU**

[74] **Messrs. SPRUSON & FERGUSON PTE LTD of AIP Law, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
**No. US62/488,691 Date: 21 April 2017 Country: United States of America
No. US62/530,753 Date: 10 April 2017 Country: United States of America
No. US62/580,400 Date: 01 November 2017 Country: United States of America**

[51] **C12N 15/63, C12N 15/13, C07K 16/28, C07K 16/46, C12N 1/15, C12N 1/19, C12N 1/21, C12N 5/10, C12P 21/08, A61K 39/395, A61P 25/00, A61P 25/28, A61P 43/00, A61P 9/10, A61P 19/00, A61P 37/06**

[57] **The present invention relates to antigen binding proteins, such as monoclonal antibodies, that specifically bind to and activate human triggering receptor expressed on myeloid cells-2 (TREM2) and pharmaceutical compositions comprising such antigen binding proteins. The agonist antigen binding proteins (e.g. antibodies) of the invention are capable of activating TREM2/DAP12 signaling in myeloid cells in the absence of Fc-mediated cross-linking of the 10 antigen binding proteins. Methods of**



treating or preventing conditions associated with TREM2 loss of function, such as Alzheimer's disease and multiple sclerosis, using the antigen binding proteins are also described.




FIG. 1A

[21] BN/N/2022/0061

[22] 25/04/2022

[54] **Method And Apparatus For Recovering C2-C4 Components In Methane-Containing Industrial Gas**

[71] **CHINA PETROLEUM & CHEMICAL CORPORATION of Chaoyang District, Beijing 100728, China**

[72] **1. SHAO, HUAWEI
2. LI, DONGFENG
3. ZOU, YI
4. LIU, ZHIXIN
5. LI, CHUNFANG
6. GUO, LIANG
7. ZHANG, JINGSHENG
8. HU, ZHIYAN**

[74] **Messrs. AIP LAW of Unit Nos. 405A-410A 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan, BS8811, Brunei Darussalam**

[31][32][33]

No. CN201911030061.1 Date: 28 October 2019 Country: United States of America

No. CN201911032377.4 Date: 28 October 2019 Country: United States of America


[86] **PCT/CN2020/117451**

[87] **WO/2021/082825**

[51] **C10G 70/06, C10G 70/04, F25J 3/02**

[57] **Disclosed are a method and a device for recovering C2 components in methane-containing gas. The method comprises the following steps: (1) cooling a compressed**

methane-containing gas and performing gas-liquid separation; (2) absorbing C2 components by using an absorbent for gas to obtain a rich absorbing liquid; (3) refluxing the rich absorbing liquid to the compressed methane-containing gas or mixing the rich absorbing liquid with the liquid obtained in step (1) to obtain a mixture solution, and reducing the pressure on the mixture solution or the rich absorbing liquid; (4) performing methane desorption on the pressure-reduced flow to obtain a rich absorbent, or performing secondary gas-liquid separation on the pressure-reduced flow, followed by methane desorption on the second liquid to obtain a rich absorbent; and (5) desorbing and separating the rich absorbent to obtain a lean absorbent and an enriched gas, and the lean absorbent is recycled and reused. The method has a high recovery rate of C2 (and above) components, as well as low overall energy consumption.



[21] BN/N/2022/0064 [22] 05/05/2022

[54] Fluid For Stabilising Solids

[71] VIRITECH LTD of Unit 6, Sheffield Road, Tinsley, Sheffield S9 1rq, United Kingdom

[72] 1. HOLCROFT, CHRISTOPHER
2. MARSHALL, MARTYN
3. GLENDENNING, MALCOLM
4. NOBLE, BRIAN

[74] Messrs. Gateway Law Corporation c/o AIP Law of AIP Law, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]
No. GB1914405.4 Date: 04 October 2019 Country: United Kingdom

[86] PCT/GB2020/052398


[87] WO/2019/074103

[51] C09K 3/22, B01J 2/00, C09K 8/80, C09K 17/12, C03C 3/078

[57] A fluid for stabilising solids formed from particulate material, the fluid comprising



glass and a carrier. A method for preparing the fluid comprising melting and fritting a glass, milling the glass to form a powder and adding the milled glass to a carrier. A method of stabilising a solid formed from particulate material, the method comprising the steps of mixing the fluid with a particulate material and setting, and the use of the fluid, in geoengineering, building preservation, construction, tunnelling, landscape restoration, land remediation, and/or flood protection/remediation.



[21] BN/N/2022/0065 [22] 02/11/2019

[54] **Stable Formulations Of Programmed Death Receptor 1 (Pd-1) Antibodies And Methods Of Use Thereof**

[71] **MERCK SHARP & DOHME CORP. of 126 East Lincoln Avenue Rahway, New Jersey 07065-0907, United States of America**

[72] 1. Manoj K. Sharma
2. Wendy Benjamin
3. Sarita Mittal
4. Ashwin Basarkar
5. Chakravarthy Nachu Narasimhan
6. Ramesh S. Kashi
7. Mohammed Shameem
8. Soumendu Bhattacharya
9. Yogita Krishnamachari

[74] **Messrs. SPRUSON & FERGUSON PTE LTD of AIP Law, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam**

[31][32][33]
No. US62/500,238 Date: 02 May 2017 Country: United States of America

[86] PCT/US2018/030459

[87] WO/2018/204368

[51] A61K 39/395 A61K 9/19 A61K 47/18 A61K 47/26 A61K 47/34

[57] The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-200 mg/mL anti- PD-1 antibody, or antigen binding fragment thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration.





FIG.1A



[21] BN/N/2022/0066

[22] 09/05/2022

[54] Small Molecule Inhibitors Of Kras G12c Mutant

[71] MERCK SHARP & DOHME CORP. of 126 East Lincoln Avenue Rahway, New Jersey 07065-0907, United States of America

[72] 1. BHARATHAN, Indu
2. GATHIAKA, Symon
3. GRAHAM, Thomas, H.
4. HAN, Yongxin
5. HENDERSON, Timothy
6. HENNESSY, Elisabeth
7. MA, Xiaoshen
8. OTTE, Ryan
9. PALANI, Anandan
10. SLOMAN, David, L.

[74] Messrs. SPRUSON & FERGUSON PTE LTD of AIP Law, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam

[31][32][33]

No. US62/926,879 Date: 28 October 2019 Country: United States of America




No. US63/030,014 Date: 26 May 2020 Country: United States of America

[86] PCT/US2020/057496

[87] WO/2021/086833

[51] C07D 471/04, C07D 498/04, A61K 31/522, A61P 35/00

[57] The disclosure provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein W1, W2, Y, Z, M, L, Cy, Cz, R1, R2, R3, R4, R2a, Ry, Rz and the subscripts m, n, q, and r are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.



[21] BN/N/2022/0067

[22] 09/05/2022

[54] Trem2 Antibodies And Uses Thereof

[71] ELI LILLY AND COMPANY of Lilly Corporate Center Indianapolis, Indiana, 46285, United States of America

[72] 1. ANDREWS, FOREST HOYT
2. FELLOWS, ROSS EDWARD
3. TANG, YING
4. WANG, YAMING

[74] Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD. c/o AIP LAW of Unit Nos. 404A-410A, 4th Floor, Wisma Jaya Jalan Pemancha, Bandar Seri Begawan, BS8811, Brunei Darussalam

[31][32][33]

No. US62/939,097 Date: 22 November 2019 Country: United States of America



[86] PCT/US2020/060663

[87] WO/2021/101823

[51] C07K 16/28, A61P 25/28

[57] The present invention relates to TREM2 antibodies, and uses thereof, for treating diseases such as neurodegenerative diseases.

[21] BN/N/2022/0068 [22] 10/05/2022

[54] Dosing Regimen For Anti-DLL3 Agents

[71] AMGEN INC. of One Amgen Center Drive Thousand Oaks, California 91320-1799
United States of America

[72] 1. SMIT, MARIE-ANNE, DAMIETTE
2. SOMAN, NEELESH
3. UPRETI, VIJAY, VISHESH
4. MINOCHA, MUKU
5. LIAO, MICHAEL
6. SHETTY, ADITYA
7. HASHEMI SADRAEI, NOOSHIN
8. NGARMCHAMNANRITH, GATAREE
9. YAGO, MARC, ANTHONY

[74] Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD. c/o AIP LAW of Unit Nos. 404A-410A, 4th Floor, Wisma Jaya Jalan Pemancha, Bandar Seri Begawan, BS8811, Brunei Darussalam

[31][32][33]

No. EP19208214.7 Date: 10 November 2019 Country: European Patent

No. US63/078,131 Date: 14 September 2019 Country: United States of America

[86] PCT/US2020/059052


[87] WO/2021/092134

[51] A61K 39/395, A61P 35/00, C07K 16/32

[57] The present invention provides a method for the treatment of DLL3-positive cancer or SCLC, comprising administering to a subject in need thereof an anti-DLL3 agent at a dose of between about 0.3 mg to about 100 mg or between about 3 mg to about 200 mg, once every two weeks. Step dosing of the anti-DLL3 agent for the treatment of SCLC is also disclosed.



FIG. 1





**REGISTRAR OF PATENT
BRUNEI DARUSSALAM**

PATENTS RULES [S 11/2013]

PATENT RENEWAL APPLICATION

Patent No.: BN/N/2014/0084
Date of Grant: 14 March, 2012
Annuity: 10th Year
Applicant(s) / Proprietor(s): PURAPIPE HOLDING LTD.
Title of Invention: Multilayer Pipeline In A Polymer Material, Device For Manufacture Of The Multilayer Pipeline And A Method For Manufacturing The Multilayer Pipeline

Patent No.: BN/N/2014/0087
Date of Grant: 12 March 2012
Annuity: 10th Year
Applicant(s) / Proprietor(s): AZMI, MOIN UZZAMAN
Title of Invention: Wash Basin With Foot Washing Facility

Patent No.: BN/N/2015/0114
Date of Grant: 14 March, 2014
Annuity: 10th Year
Applicant(s) / Proprietor(s): HUWE INC.
Title of Invention: Hammer Union Wrench

Patent No.: RE/R/2017/0004
Date of Grant: 25 January, 2017
Annuity: 7th Year
Applicant(s) / Proprietor(s): TOTAL S.A.



Title of Invention: Heating Cover For A Device For Transporting A Fluid Containing A Hydrocarbon

Patent No.: RE/R/2017/0049

Date of Grant: 21 March, 2017

Annuity: 6th Year

Applicant(s) / Proprietor(s): EISAI R&D MANAGEMENT CO., LTD

Title of Invention: Cyclopropane Compounds

Patent No.: RE/R/2017/0055

Date of Grant: 15 March, 2017

Annuity: 6th Year

Applicant(s) / Proprietor(s): EISAI R&D MANAGEMENT CO., LTD

Title of Invention: Condensed Aminodihydrothiazine Derivative

Patent No.: BN/N/2016/0080

Date of Grant: 13 April, 2014

Annuity: 8th Year

Applicant(s) / Proprietor(s): THERMTECH HOLDING AS

Title of Invention: Method Of Treating A Material

Patent No.: RE/R/2012/0031

Date of Grant: 02 April, 2009

Annuity: 14th Year

Applicant(s) / Proprietor(s): MERCK SHARP & DOHME CORP.

Title of Invention: Hydroxymethyl Pyrrolidines As Beta 3 Adrenergic Receptor Agonists

Patent No.: RE/R/2013/0076

Date of Grant: 31 March, 2009



Annuity: 14th Year
Applicant(s) / Proprietor(s): HYDROBALL TECHNICS HOLDINGS PTE LTD
Title of Invention: Cleaning System For Cleaning Tubing

Patent No.: RE/R/2014/0008
Date of Grant: 11 April, 2013
Annuity: 10th Year
Applicant(s) / Proprietor(s): EWOOTEC CO., LTD.
Title of Invention: Apparatus And Method For Detecting Location Of Underground Facility

Patent No.: RE/R/2014/0059
Date of Grant: 30 April, 2014
Annuity: 9th Year
Applicant(s) / Proprietor(s): UNIDENSE TECHNOLOGY GMBH
Title of Invention: Catalyst Loading System

Patent No.: RE/R/2015/0039
Date of Grant: 10 September, 2014
Annuity: 8th Year
Applicant(s) / Proprietor(s): ALMIRALL S.A.
Title of Invention: Combinations Comprising Antimuscarinic Agents And Beta-Adrenergic Agonists

Patent No.: RE/R/2016/0032
Date of Grant: 23 March, 2016
Annuity: 7th Year
Applicant(s) / Proprietor(s): MERCK SHARP & DOHME CORP.
Title of Invention: Inhibitors Of Hepatitis C Virus Replication



Patent No.: RE/R/2017/0014
Date of Grant: 15 April, 2016
Annuity: 7th Year
Applicant(s) / Proprietor(s): SCYNEXIS. INC.
Title of Invention: Antifungal Agents

Patent No.: RP/R/2006/0012
Date of Grant: 22 March, 2006
Annuity: 17th Year
Applicant(s) / Proprietor(s): MERCK SHARPE & DOHME CORP.
Title of Invention: Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes

Patent No.: RP/R/2006/0012
Date of Grant: 22 March, 2006
Annuity: 16th Year
Applicant(s) / Proprietor(s): MERCK SHARPE & DOHME CORP.
Title of Invention: Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes

Patent No.: BN/N/2016/0086
Date of Grant: 05 May, 2015
Annuity: 8th Year
Applicant(s) / Proprietor(s): ASTRAZENECA AB
Title of Invention: Imidazo[4,5-C]Quinolin-2-One Compounds And Their Use In Treating Cancer



Patent No.:	BN/N/2017/0093
Date of Grant:	03 May, 2016
Annuity:	7th Year
Applicant(s) / Proprietor(s):	ASTRAZENECA AB
Title of Invention:	Pyrazole Derivatives Useful As 5-Lipoxygenase Activating Protein (Flap) Inhibitors

Patent No.:	BN/N/2018/0078
Date of Grant:	02 March, 2017
Annuity:	6th Year
Applicant(s) / Proprietor(s):	SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V.
Title of Invention:	Chemically-Selective Imager For Imaging Fluid Of A Subsurface Formation And Method Of Using Same

Patent No.:	RE/R/2012/0004
Date of Grant:	29 April, 2011
Annuity:	12th Year
Applicant(s) / Proprietor(s):	SUMITOMO METAL INDUSTRIES LTD VALLOUREC MANNESMANN OIL & GAS FRANCE
Title of Invention:	Threaded Joint For Steel Pipes

Patent No.:	RE/R/2016/0005
Date of Grant:	03 March, 2015
Annuity:	8th Year
Applicant(s) / Proprietor(s):	CRYSTAL LAGOONS (CURACAO) B.V.
Title of Invention:	Method And System For The Sustainable Cooling Of Industrial Processes

Patent No.:	RE/R/2017/0015
--------------------	-----------------------



Date of Grant: 04 April, 2016
Annuity: 16th Year
Applicant(s) / Proprietor(s): GILEAD SCIENCES, INC.
Title of Invention: Modulators Of Pharmacokinetic Properties Of Therapeutics

Patent No.: RE/R/2017/0020
Date of Grant: 10 May, 2016
Annuity: 7th Year
Applicant(s) / Proprietor(s): GILEAD SCIENCES, INC.
JAPAN TOBACCO, INC.
Title of Invention: Methods For Improving The Pharmacokinetics Of HIV Intergase

Patent No.: RE/R/2018/0014
Date of Grant: 05 April, 2017
Annuity: 6th Year
Applicant(s) / Proprietor(s): VERTEX PHARMACEUTICALS INCORPORATED
Title of Invention: Modulators Of ATP-Binding Cassette Transporters

Patent No.: RE/R/2019/0008
Date of Grant: 23 May, 2018
Annuity: 5th Year
Applicant(s) / Proprietor(s): BIOCRYST PHARMACEUTICALS, INC.
Title of Invention: Intravenous Antiviral Treatments

Patent No.: RP/R/2006/0006
Date of Grant: 02 May, 2003
Annuity: 20th Year
Applicant(s) / Proprietor(s): ASTRAZENECA AB



Title of Invention: **Novel Form Of S-Omeprazole**

Patent No.: **RP/R/2007/0030**

Date of Grant: **30 April, 2007**

Annuity: **16th Year**

Applicant(s) / Proprietor(s): **SANOFI-AVENTIS**

Title of Invention: **Polymorphic Clopidogrel Hydrogegensulphate Form**

Patent No.: **RP/R/2008/0073**

Date of Grant: **30 April, 2008**

Annuity: **15th Year**

Applicant(s) / Proprietor(s): **JANSSEN ALZHEIMER IMMUNOTHERAPY**

Title of Invention: **Prevention And Treatment Of Amyloidogenic Disease**

Patent No.: **BN/N/2019/0117**

Date of Grant: **20 April, 2018**

Annuity: **5th Year**

Applicant(s) / Proprietor(s): **AMGEN INC.**

Title of Invention: **Trem2 Antigen Binding Proteins And Uses Thereof**

Patent No.: **RE/R/2015/0024**

Date of Grant: **13 April, 2015**

Annuity: **8th Year**

Applicant(s) / Proprietor(s): **HELSINN HEALTHCARE SA**

Title of Invention: **Compositions For Treating Centrally Mediated Nausea And Vomiting**

Patent No.: **RE/R/2016/0014**

Date of Grant: **17 April, 2015**



Annuity:	8th Year
Applicant(s) / Proprietor(s):	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Title of Invention:	Methods And Systems For Phylogenetic Analysis
<hr/>	<hr/>
Patent No.:	RE/R/2017/0007
Date of Grant:	15 April, 2016
Annuity:	7th Year
Applicant(s) / Proprietor(s):	MERCK SHARP & DOHME CORP.
Title of Invention:	Treating Allergic And Inflammatory Conditions
<hr/>	<hr/>
Patent No.:	RE/R/2017/0017
Date of Grant:	15 April, 2016
Annuity:	7th Year
Applicant(s) / Proprietor(s):	HALLIBURTON ENERGY SERVICES, INC
Title of Invention:	Extending Lines Through And Preventing Extrusion Of, Seal Elements Of Packer Assemblies
<hr/>	<hr/>
Patent No.:	RE/R/2018/0006
Date of Grant:	14 April, 2017
Annuity:	6th Year
Applicant(s) / Proprietor(s):	PURDUE PHARMA L.P.
Title of Invention:	Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising An Opioid Analgesic
<hr/>	<hr/>
Patent No.:	RE/R/2018/0016
Date of Grant:	14 April, 2017
Annuity:	6th Year
Applicant(s) / Proprietor(s):	GENENTECH, INC.



Title of Invention: Compositions And Methods Containing Alkylglycosides For Stabilizing Protein-Containing Formulations

Patent No.: RE/R/2018/0036

Date of Grant: 2 April, 2018

Annuity: 5th Year

Applicant(s) / Proprietor(s): OFFICINE MACCAFERRI S.P.A.

Title of Invention: A Protective Metal Netting With Interwoven Wires, And A Machine And A Method For Its Manufacture

Patent No.: BN/N/2016/0084

Date of Grant: 20 May, 2014

Annuity: 8th Year

Applicant(s) / Proprietor(s): DAICEL CORPORATION

Title of Invention: Flange Fastening Skill Determination Apparatus And Flange Fastening Skill Determination Program

Patent No.: BN/N/2018/0053

Date of Grant: 04 June, 2014

Annuity: 5th Year

Applicant(s) / Proprietor(s): THE UNIVERSITY OF BRITISH COLUMBIA

Title of Invention: Anti-Fibrogenic Compounds, Method And Uses Thereof

Patent No.: RE/R/2013/0046

Date of Grant: 18 January, 2003

Annuity: 20th Year

Applicant(s) / Proprietor(s): TAKEDA PHARMACEUTICAL COMPANY LIMITED

Title of Invention: Solid Preparation Comprising Alogliptin And Pioglitazone

Patent No.: RE/R/2013/0056



Date of Grant:	28 February, 2013
Annuity:	10th Year
Applicant(s) / Proprietor(s):	CONOCOPHILLIPS COMPANY
Title of Invention:	Noninvasive Measurement And Control System For Use In Hydrocarbon Processing

Patent No.:	RE/R/2015/0016
Date of Grant:	26 February, 2014
Annuity:	9th Year
Applicant(s) / Proprietor(s):	UCB PHARMA GMBH
Title of Invention:	New Chirla Intermediate, Process For Producing The Same And Its Use In The Manufacture Of Telerodine, Fesoterodine, Or The Active Metabolite Thereof

Patent No.:	RE/R/2017/0003
Date of Grant:	3 February, 2016
Annuity:	7th Year
Applicant(s) / Proprietor(s):	MERIDIAN MEDICAL TECHNOLOGIES, INC.
Title of Invention:	Automatic Injector

Patent No.:	BN/N/2015/0093
Date of Grant:	11 August, 2015
Annuity:	6th Year
Applicant(s) / Proprietor(s):	UNIVERSITI BRUNEI DARUSSALAM
Title of Invention:	A Method To Enhance The Efficiency Of Dye Sensitized And Perovskite Solar Cell

Patent No.:	BN/N/2015/0093
Date of Grant:	11 August, 2015
Annuity:	7th Year
Applicant(s) / Proprietor(s):	UNIVERSITI BRUNEI DARUSSALAM



Title of Invention: A Method To Enhance The Efficiency Of Dye Sensitized And Perovskite Solar Cell

Patent No.: BN/N/2016/0017

Date of Grant: 31 March, 2016

Annuity: 5th Year

Applicant(s) / Proprietor(s): UNIVERSITI BRUNEI DARUSSALAM
PIXELA CORPORATION

Title of Invention: Thermo-Shielding Window Coating Composition And Method

Patent No.: BN/N/2016/0017

Date of Grant: 31 March, 2016

Annuity: 6th Year

Applicant(s) / Proprietor(s): UNIVERSITI BRUNEI DARUSSALAM
PIXELA CORPORATION

Title of Invention: Thermo-Shielding Window Coating Composition And Method

Patent No.: BN/N/2016/0017

Date of Grant: 31 March, 2016

Annuity: 7th Year

Applicant(s) / Proprietor(s): UNIVERSITI BRUNEI DARUSSALAM
PIXELA CORPORATION

Title of Invention: Thermo-Shielding Window Coating Composition And Method

Patent No.: BN/N/2018/0092

Date of Grant: 31 March, 2016

Annuity: 5th Year

Applicant(s) / Proprietor(s): UNIVERSITI BRUNEI DARUSSALAM

Title of Invention: Anti-Corrosion Electrolyte Coating System And Method



Patent No.: BN/N/2018/0092
Date of Grant: 31 March, 2016
Annuity: 6th Year
Applicant(s) / Proprietor(s): UNIVERSITI BRUNEI DARUSSALAM
Title of Invention: Anti-Corrosion Electrolyte Coating System And Method

Patent No.: BN/N/2018/0092
Date of Grant: 31 March, 2016
Annuity: 7th Year
Applicant(s) / Proprietor(s): UNIVERSITI BRUNEI DARUSSALAM
Title of Invention: Anti-Corrosion Electrolyte Coating System And Method



REGISTRAR OF PATENT

BRUNEI DARUSSALAM

PATENTS RULES [S 11/2013]

PATENT GRANTED UNDER SECTION 30

Application No.: BN/N/2012/0024

Date of Grant: 20 June, 2014

Applicant(s) / Proprietor(s): UDRA ENTERPRISE

Title of Invention: Fully Window Shade

Application No.: BN/N/2015/0099

Date of Grant: 16 December, 2021

Applicant(s) / Proprietor(s): VISION GLOBAL HOLDINGS LTD.

Title of Invention: Pharmaceutical Composition Comprising Albumin-Binding Arginine Deiminase For Cancer Targeting Treatment

Application No.: BN/N/2016/0023

Date of Grant: 21 May, 2022

Applicant(s) / Proprietor(s): HALLIBURTON ENERGY SERVICES, INC.

Title of Invention: Intervention Tool For Delivering Self-Assembling Repair Fluid

Application No.: BN/N/2016/0024

Date of Grant: 19 March, 2022

Applicant(s) / Proprietor(s): ASTRAZENECA AB

Title of Invention: Therapeutic Polymeric Nanoparticles And Methods Of Making And Using Same

Application No.: BN/N/2018/0115

Date of Grant: 21 February, 2022



Applicant(s) / Proprietor(s): HALLIBURTON ENERGY SERVICES, INC.
Title of Invention: Shunt System For Downhole Sand Control Completions

Application No.: BN/N/2019/0060
Date of Grant: 19 February, 2022
Applicant(s) / Proprietor(s): HALLIBURTON ENERGY SERVICES, INC.
Title of Invention: Flow Control Devices With Pressure-Balanced Pistons

Application No.: BN/N/2019/0068
Date of Grant: 13 December, 2021
Applicant(s) / Proprietor(s): IDG FINANCE S.À.R.L.
Title of Invention: Air Blast Valve

Application No.: BN/N/2019/0117
Date of Grant: 19 May, 2022
Applicant(s) / Proprietor(s): AMGEN INC.
Title of Invention: Trem2 Antigen Binding Proteins And Uses Thereof

Application No.: BN/N/2020/0063
Date of Grant: 25 May, 2022
Applicant(s) / Proprietor(s): NKMAX CO., LTD.
Title of Invention: Method Of Producing Natural Killer Cells And Composition For Treating Cancer

Application No.: BN/N/2020/0106
Date of Grant: 15 March, 2022
Applicant(s) / Proprietor(s): SATO PHARMACEUTICAL CO., LTD.
Title of Invention: Application Container



Application No.: BN/N/2021/0017
Date of Grant: 17 February, 2022
Applicant(s) / Proprietor(s): ASTRAZENECA AB
Title of Invention: Dendrimer Formulations

Application No.: BN/N/2021/0073
Date of Grant: 20 April, 2022
Applicant(s) / Proprietor(s): AMGEN INC.
Title of Invention: Alkyl Dihydroquinoline Sulfonamide Compounds

Application No.: BN/N/2021/0076
Date of Grant: 28 May, 2022
Applicant(s) / Proprietor(s): ASTRAZENECA AB
Title of Invention: Fused Tricyclic Compounds Useful As Anticancer Agents



REGISTRAR OF PATENT

BRUNEI DARUSSALAM

PATENTS RULES [S 11/2013]

RECORDAL OF CHANGE OF NAME

(The name in *italic* is the previous proprietor's name)

Application No.: BN/N/2016/0002

Applicant(s) / Proprietor(s): CJ HEALTHCARE CORPORATION
HK INNO.N CORPORATION

Title of Invention: A CONNECTOR FOR TUBULAR ELEMENTS

Agent and/ or Address for Service : Messrs. AIP LAW of Unit Nos. 404A-410A, 4th Floor,
Wisma Jaya Jalan Pemancha, Bandar Seri Begawan, BS8811, Brunei Darussalam.
